Ma 2019b.

Methods	Study design: Randomised clinical trial Study duration: January 2013 to February 2016 Duration of follow‐up: 2 years
Participants	Age (mean ± SD): TACE + MWA: 53.72 ± 8.72 years; TACE alone: 53.24 ± 8.45 years Male (n/total): TACE + MWA: 26/41; TACE alone: 24/41 Tumour diameter (mean ± SD): TACE + MWA: 49.82 ± 11.27 mm; TACE: 50.15 ± 11.62 mm
Interventions	TACE + MWA group: TACE: Chemotherapeutic drugs: oxaliplatin 100 mg. 1‐2 sessions of TACE, with an interval of 4 weeks RFA: The interval between TACE and RFA was 1 week. CT‐guided RFA TACE group: Chemotherapeutic drugs: oxaliplatin 100 mg. 1‐2 sessions of TACE, with an interval of 4 weeks
Outcomes	Tumour response: measured by CT image Survival rate Recurrence rate
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.